WO1998009985A2 - Anti-inflammatory peptides and uses thereof - Google Patents
Anti-inflammatory peptides and uses thereof Download PDFInfo
- Publication number
- WO1998009985A2 WO1998009985A2 PCT/IL1997/000295 IL9700295W WO9809985A2 WO 1998009985 A2 WO1998009985 A2 WO 1998009985A2 IL 9700295 W IL9700295 W IL 9700295W WO 9809985 A2 WO9809985 A2 WO 9809985A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- arg
- glu
- peptide
- derivative
- inflammatory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
- C07K5/06095—Arg-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
- C07K5/123—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- MIF aldose reductase inhibitor
- the peptide derivative is more resistant to proteolytic degradation than the corresponding nonderivatized peptide.
- a peptide derivative having D-amino acid substitution (s) in place of a L-amino acid resists proteolytic cleavage when administered to a mammal.
- the peptide derivative has increased permeability across a cell membrane than the corresponding nonderivatized peptide, e.g., those peptide derivatives having a lipophilic moiety coupled at the amino and/or carboxyl terminus.
- the peptide derivative has enhanced biological activity, e.g., those peptide derivatives which are dualized or multimerized peptides.
- the macrophages can be labeled with any suitable marker (such as fluorescein or rhodamine) , or a radioactive marker (such as a radioactive isotope of iodine, chromium, carbon, or hydrogen) .
- the assay can be performed with unlabeled cells; the cells can be detected by any suitable method, such as microscopically, with or without staining.
- An in vitro macrophage migration assay is described in Hirschberg and Schwartz, 1995, J. Neuroimmunol. 61:89-96.
- T cell activities such as adhesion to fibronectin or extracellular matrix, interleukin-2 (IL-2) production, etc.
- IL-2 interleukin-2
- An in vitro assay measuring T cell adhesion is described in Section 7, infra .
- the methods of the present invention also provide for the treatment of a subject in need of such treatment to inhibit a humoral and/or cellular immune response by administration of a therapeutic composition comprising a peptide or peptide derivative of the present invention and a pharmaceutically acceptable carrier.
- the subject is preferably an animal, including but not limited to animals such as cows, pigs, chickens, etc., and is preferably a mammal, and most preferably a human.
- mice Female Lewis rats, which are genetically susceptible to multiple sclerosis, were injected intradermally with 100 ⁇ g of a fragment of myelin basic protein (amino acid residues 68-88) (MBP) (see, Chou et al., 5 1977, J. Neurobiol. 28:115) isolated from guinea pig spinal cord and mixed with Freund's complete adjuvant.
- MBP myelin basic protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU40301/97A AU4030197A (en) | 1996-09-03 | 1997-09-03 | Anti-inflammatory peptides and uses thereof |
IL12852997A IL128529A0 (en) | 1996-09-03 | 1997-09-03 | Anti-inflammatory peptides and uses thereof |
CA002264285A CA2264285A1 (en) | 1996-09-03 | 1997-09-03 | Anti-inflammatory peptides and uses thereof |
EP97937794A EP0927191A2 (en) | 1996-09-03 | 1997-09-03 | Anti-inflammatory peptides and uses thereof |
JP10512435A JP2001500492A (en) | 1996-09-03 | 1997-09-03 | Anti-inflammatory peptides and uses thereof |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2537696P | 1996-09-03 | 1996-09-03 | |
US75314196A | 1996-11-20 | 1996-11-20 | |
US08/864,301 | 1997-05-28 | ||
US08/753,141 | 1997-05-28 | ||
US08/864,301 US6126939A (en) | 1996-09-03 | 1997-05-28 | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
US60/025,376 | 1997-05-28 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1998009985A2 true WO1998009985A2 (en) | 1998-03-12 |
WO1998009985A3 WO1998009985A3 (en) | 1998-05-07 |
WO1998009985B1 WO1998009985B1 (en) | 1998-06-18 |
Family
ID=27362525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL1997/000295 WO1998009985A2 (en) | 1996-09-03 | 1997-09-03 | Anti-inflammatory peptides and uses thereof |
Country Status (7)
Country | Link |
---|---|
US (1) | US6126939A (en) |
EP (1) | EP0927191A2 (en) |
JP (1) | JP2001500492A (en) |
AU (1) | AU4030197A (en) |
CA (1) | CA2264285A1 (en) |
IL (1) | IL128529A0 (en) |
WO (1) | WO1998009985A2 (en) |
Cited By (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000077166A2 (en) * | 1999-06-10 | 2000-12-21 | Digital Gene Technologies, Inc. | Gene expression modulated in gastrointestinal inflammation |
WO2001010457A2 (en) * | 1999-08-09 | 2001-02-15 | Tripep Ab | Pharmaceutical compositions containing tripeptides |
WO2001010456A2 (en) * | 1999-08-09 | 2001-02-15 | Tripep Ab | Peptides that block viral infectivity and methods of use thereof |
US6593455B2 (en) | 2001-08-24 | 2003-07-15 | Tripep Ab | Tripeptide amides that block viral infectivity and methods of use thereof |
WO2002083729A3 (en) * | 2001-04-18 | 2003-07-31 | Univ Open | Polypeptides derived from amyloid precursor peptide (app) and their uses |
WO2003064665A2 (en) | 2002-02-01 | 2003-08-07 | Oxford Biomedica (Uk) Limited | Viral vector |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
WO2004002417A2 (en) | 2002-06-28 | 2004-01-08 | Centocor, Inc. | Mammalian ch1 deleted mimetibodies, compositions, methods and uses |
JP2004513079A (en) * | 2000-08-10 | 2004-04-30 | エス・アイ・エス・シユロブ・インステイテユート・フオー・サイエンス・リミテツド | Pharmaceutical composition comprising an analgesic peptide |
EP1472276A2 (en) * | 2001-02-28 | 2004-11-03 | Keith M. Skubitz | Small peptides capable of modulating the function of cd66 (ceacam) family members |
WO2005030242A1 (en) * | 2003-09-26 | 2005-04-07 | University Of Florida Research Foundation, Inc | Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
WO2005090387A2 (en) * | 2004-03-23 | 2005-09-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Histone h2a peptide derivatives and analogs and methods of use thereof |
US6969598B2 (en) | 2001-04-30 | 2005-11-29 | Oxford Biomedica (Uk) Limited | Methods for producing high titre vectors and compositions used in such methods |
WO2005115996A1 (en) | 2004-05-24 | 2005-12-08 | Sterix Limited | Sulfamic acid ester compounds useful in the inhibition of seroid sulphatase activity and aromatase activity |
US7012129B2 (en) | 2001-09-19 | 2006-03-14 | Tripep Ab | Antiviral composition comprising glycine amide |
WO2006101187A1 (en) * | 2005-03-22 | 2006-09-28 | Rohto Pharmaceutical Co., Ltd. | Peptides that increase collagen or hyaluronic acid production |
WO2006116731A2 (en) * | 2005-04-27 | 2006-11-02 | The Procter & Gamble Company | Personal care compositions comprising a dipeptide |
FR2894142A1 (en) * | 2005-12-05 | 2007-06-08 | Oreal | Use of a combination of niacinamide and tyrosine-arginine dipeptide or its derivatives e.g. to prevent and/or decrease cutaneous rednesses and/or swellings |
WO2007072056A2 (en) | 2005-12-22 | 2007-06-28 | Oxford Biomedica (Uk) Limited | Vectors |
WO2008096155A1 (en) | 2007-02-08 | 2008-08-14 | Sterix Limited | Composition comprising a glycolytic inhibitor and a ring system comprising a sulphamate group for the treatment of cancer |
US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
US7491702B2 (en) | 2001-04-18 | 2009-02-17 | The Open University | Polypeptides related to amyloid precursor protein, pharmaceutical compositions thereof, and methods of treatment using the same |
WO2008096276A3 (en) * | 2007-02-02 | 2009-03-19 | Greenpharma Sas | Peptide inhibitors of metallo- ectopeptidases, compositions comprising said compounds and their pharmaceutical and cosmetic uses |
US20090105157A1 (en) * | 2006-05-30 | 2009-04-23 | Obschestvo Ogranichennoi Otvetstennostyu Sia Peptides | Peptide substance stimulating regeneration of central nervous system neurons, pharmaceutical composition on its base, and the method of its application |
US7528227B2 (en) | 2004-03-23 | 2009-05-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Histone H2A peptide derivatives and uses thereof |
WO2009123486A1 (en) * | 2008-04-01 | 2009-10-08 | Bioalvo - Serviços, Investigação E Desenvolvimento Em Biotecnologia S.A. | Use of compounds in the treatment of tau-induced cytotoxicities |
US7605132B2 (en) | 2001-08-29 | 2009-10-20 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Protective factors against inflammation, burns and noxious stimuli |
US7622446B2 (en) | 2001-04-18 | 2009-11-24 | The Open University | Polypeptides, derivatives and uses thereof |
WO2010055413A1 (en) | 2008-11-12 | 2010-05-20 | Fondazione Centro San Raffaele Del Monte Tabor | Gene vector for inducing transgene-specific immune tolerance |
EP2194137A2 (en) | 2000-04-19 | 2010-06-09 | Oxford BioMedica (UK) Limited | Cells comprising codon optimized retroviral particles |
EP2202240A1 (en) | 2000-08-18 | 2010-06-30 | Sterix Limited | Compound |
US7855181B2 (en) | 1999-08-13 | 2010-12-21 | University Of Florida Research Foundation, Inc. | Dipeptides for prevention of muscle breakdown and microbial infection |
WO2011023989A1 (en) | 2009-08-24 | 2011-03-03 | Sterix Limited | Aromatase inhibitor |
EP2298860A2 (en) | 2005-12-21 | 2011-03-23 | BioEos Limited | Method of producing rough strains of bacteria and uses thereof |
US7968561B2 (en) | 2006-03-01 | 2011-06-28 | Sterix Limited | Steroidal compounds as steroid sulphatase inhibitors |
US8119627B2 (en) | 2005-07-04 | 2012-02-21 | Sterix Limited | Heterocyclic compounds as inhibitors of 17beta-HSD3 |
US8143380B2 (en) | 2004-07-08 | 2012-03-27 | Amgen Inc. | Therapeutic peptides |
WO2012156839A2 (en) | 2011-05-19 | 2012-11-22 | Ospedale San Raffaele S.R.L. | New generation of splice-less lentiviral vectors for safer gene therapy applications |
CN102796165A (en) * | 2011-05-24 | 2012-11-28 | 首都医科大学 | Arg-Tyr modified aliphatic amine/ alcohol derivatives and preparation method and application thereof |
US8394825B2 (en) | 2007-03-28 | 2013-03-12 | Sterix Limited | Compound |
EP2594284A1 (en) | 2006-04-21 | 2013-05-22 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
US8470860B2 (en) | 2004-06-04 | 2013-06-25 | Sterix Limited | Phenyl-sulfamates as aromatase inhibitors |
US8558028B2 (en) | 2007-11-20 | 2013-10-15 | University Of Bath Of Claverton Down | Compound capable of inhibiting 17-beta hydroxysteriod dehydrogenase |
US8642295B2 (en) | 2007-01-11 | 2014-02-04 | Erasmus University Medical Center | Circular chromosome conformation capture (4C) |
WO2014140934A2 (en) | 2013-03-11 | 2014-09-18 | Life Science Nutrition As | Natural lipids containing non-oxidizable fatty acids |
US8858968B2 (en) | 2005-12-05 | 2014-10-14 | L'oreal | Use of tyrosine-arginine dipeptide and niacinamide as substance P antagonist |
US9145450B2 (en) | 1998-10-23 | 2015-09-29 | Amgen Inc. | Thrombopoietic compounds |
US20160002308A1 (en) * | 2013-01-10 | 2016-01-07 | Supadelixir Inc. | Microphthalmia-associated transcription factor-derived peptide and composition containing same |
WO2016009326A1 (en) | 2014-07-14 | 2016-01-21 | Ospedale San Raffaele S.R.L | Vector production |
EP3002330A1 (en) | 2005-05-27 | 2016-04-06 | Ospedale San Raffaele S.r.l. | Gene vector |
WO2016063264A1 (en) | 2014-10-24 | 2016-04-28 | Ospedale San Raffaele S.R.L. | Permanent epigenetic gene silencing |
AU2014271339B2 (en) * | 2005-04-27 | 2016-11-03 | The Procter & Gamble Company | Personal care compositions |
EP3192874A1 (en) | 2008-06-18 | 2017-07-19 | Oxford BioMedica (UK) Limited | Virus purification |
WO2018193118A1 (en) | 2017-04-21 | 2018-10-25 | Ospedale San Raffaele S.R.L | Gene therapy |
US10130577B2 (en) | 2005-04-27 | 2018-11-20 | The Procter & Gamble Company | Personal care compositions |
US10188740B2 (en) | 2005-08-12 | 2019-01-29 | Amgen Inc. | Modified Fc molecules |
US10391201B2 (en) | 2014-04-25 | 2019-08-27 | Ospedale San Raffaele Srl | Gene therapy |
WO2019219836A1 (en) | 2018-05-16 | 2019-11-21 | Ospedale San Raffaele S.R.L. | Virus vector production |
WO2019219838A1 (en) | 2018-05-16 | 2019-11-21 | Ospedale San Raffaele S.R.L. | Compositions and methods for haematopoietic stem cell transplantation |
EP3587582A1 (en) | 2013-10-24 | 2020-01-01 | Adaptimmune Limited | Vectors for transgene expression |
WO2020002380A1 (en) | 2018-06-25 | 2020-01-02 | Ospedale San Raffaele S.R.L | Gene therapy |
EP3613859A1 (en) | 2013-10-24 | 2020-02-26 | Ospedale San Raffaele S.r.l. | Method |
WO2020074729A1 (en) | 2018-10-11 | 2020-04-16 | Ospedale San Raffaele S.R.L | Selection by means of artificial transactivators |
CN111093687A (en) * | 2017-09-15 | 2020-05-01 | 凯恩塞恩斯株式会社 | Use of peptides as therapeutic agents for autoimmune diseases and bone diseases |
EP3650548A1 (en) | 2013-12-20 | 2020-05-13 | Oxford BioMedica (UK) Limited | Viral vector production system |
EP3549595A4 (en) * | 2016-12-05 | 2020-07-22 | Otsuka Pharmaceutical Co., Ltd. | Amyotrophy inhibiting composition |
WO2020148445A1 (en) | 2019-01-18 | 2020-07-23 | Société des Produits Nestlé S.A. | Agents and methods for increasing stem cell function |
EP3733214A1 (en) | 2009-04-30 | 2020-11-04 | Ospedale San Raffaele S.r.l. | Gene vector |
CN112724238A (en) * | 2021-01-21 | 2021-04-30 | 浙江辉肽生命健康科技有限公司 | Bioactive peptide with amino acid structure FREGTTPKPK, and preparation method and application thereof |
WO2021094752A1 (en) | 2019-11-12 | 2021-05-20 | Oxford Biomedica (Uk) Limited | Production system |
WO2021160993A1 (en) | 2020-02-13 | 2021-08-19 | Oxford Biomedica (Uk) Limited | Production of lentiviral vectors |
WO2021181108A1 (en) | 2020-03-13 | 2021-09-16 | Oxford Biomedica (Uk) Limited | Lentiviral vectors |
WO2021229242A1 (en) | 2020-05-15 | 2021-11-18 | Oxford Biomedica (Uk) Limited | Viral vector production |
WO2021229237A1 (en) | 2020-05-14 | 2021-11-18 | Ucl Business Ltd | Cyclosporine analogues |
GB202114529D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral vectors |
GB202114530D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Retroviral vectors |
GB202114532D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral Vectors |
WO2022064061A1 (en) | 2020-09-28 | 2022-03-31 | Société des Produits Nestlé S.A. | Compositions and methods for increasing stem cell function |
WO2022064063A1 (en) | 2020-09-28 | 2022-03-31 | Société des Produits Nestlé S.A. | Compositions and methods for increasing stem cell function |
WO2022101617A1 (en) | 2020-11-10 | 2022-05-19 | Oxford Biomedica (Uk) Limited | Preparation of a solution of polymer/nucleic acid complexes |
WO2022162247A1 (en) | 2021-02-01 | 2022-08-04 | Epsilen Bio S.R.L. | Gene silencing |
WO2022229227A1 (en) | 2021-04-28 | 2022-11-03 | Ospedale San Raffaele S.R.L. | Compositions for improving the transduction of cells by viral vectors |
WO2022233767A1 (en) | 2021-05-05 | 2022-11-10 | Société des Produits Nestlé S.A. | Urolithin for increasing stem cell function |
WO2023062363A1 (en) | 2021-10-12 | 2023-04-20 | Oxford Biomedica (Uk) Limited | Lentiviral vectors |
WO2023062359A2 (en) | 2021-10-12 | 2023-04-20 | Oxford Biomedica (Uk) Limited | Novel viral regulatory elements |
WO2023066735A1 (en) | 2021-10-19 | 2023-04-27 | Ospedale San Raffaele S.R.L. | Gene therapy |
WO2023105235A1 (en) | 2021-12-09 | 2023-06-15 | Oxford Biomedica (Uk) Limited | Purification method of viral vectors |
WO2023209225A1 (en) | 2022-04-29 | 2023-11-02 | Ospedale San Raffaele S.R.L. | Gene therapy |
WO2023209223A1 (en) | 2022-04-28 | 2023-11-02 | Ospedale San Raffaele S.R.L. | Methods for haematopoietic stem cell transplantation |
WO2023247937A1 (en) | 2022-06-21 | 2023-12-28 | Ucl Business Ltd | Cyclosporine analogues |
US11939398B2 (en) | 2016-08-16 | 2024-03-26 | Neuro-Bio Ltd | Modified peptides for use in treating neurodegenerative disorders |
WO2024079644A1 (en) | 2022-10-11 | 2024-04-18 | Fondazione Telethon Ets | 3d cell culture methods |
US12059478B2 (en) | 2016-05-20 | 2024-08-13 | Ospedale San Raffaele S.R.L. | Gene therapy |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7074888B1 (en) * | 1995-03-17 | 2006-07-11 | The Research Foundation Of State University Of New York | Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX |
FR2767135B1 (en) * | 1997-08-06 | 2002-07-12 | Genset Sa | LSR COMPLEX RECEPTOR, ACTIVITY, CLONING, AND APPLICATION TO DIAGNOSIS, PREVENTION AND / OR TREATMENT OF OBESITY AND THE RISKS OR COMPLICATIONS THEREOF |
SE9703531D0 (en) * | 1997-09-30 | 1997-09-30 | Rudolf Valenta | Non-anaphlactic forms of allergens and their use |
CA2225325A1 (en) * | 1997-12-19 | 1999-06-19 | The University Of British Columbia | Hemiasterlin analogs |
WO1999046283A1 (en) * | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
AR023819A1 (en) * | 1999-05-03 | 2002-09-04 | Astrazeneca Ab | PHARMACEUTICAL FORMULATION, KIT OF PARTS AND USE OF THE FORMULATION |
NZ517250A (en) * | 1999-08-10 | 2004-12-24 | Uab Research Foundation | Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs (NSAID) and naturally occurring conotoxins |
US6989367B2 (en) * | 2000-01-14 | 2006-01-24 | Genset S.A. | OBG3 globular head and uses thereof |
US20020058617A1 (en) * | 2000-01-14 | 2002-05-16 | Joachim Fruebis | OBG3 globular head and uses thereof for decreasing body mass |
US7338787B2 (en) * | 2000-01-14 | 2008-03-04 | Serono Genetics Institute S.A. | Nucleic acids encoding OBG3 globular head and uses thereof |
US6858581B2 (en) * | 2000-06-16 | 2005-02-22 | Arizona State University | Chemically-modified peptides, compositions, and methods of production and use |
US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
DE60131033T2 (en) * | 2000-08-25 | 2008-07-17 | Research Corp. Technologies, Inc., Tucson | Uses of anticonvulsant amino acid for the treatment of bipolar disorders |
EP1243262B1 (en) * | 2001-03-20 | 2006-05-31 | Schwarz Pharma Ag | Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain |
DK1243263T3 (en) * | 2001-03-21 | 2003-03-17 | Sanol Arznei Schwarz Gmbh | Hitherto unknown use of a class of peptide compounds to treat allodynia or other various types of chronic or phantom pain |
US6908899B2 (en) * | 2001-08-17 | 2005-06-21 | U.S. Dept. Of Veterans Affairs | Pro-inflammatory fibrinopeptide |
JP4485367B2 (en) | 2002-12-03 | 2010-06-23 | パソゲン リムーバル アンド ダイアグノスティック テクノロジーズ インコーポレイテッド | Prion protein ligands and methods of use |
WO2004094457A2 (en) * | 2003-04-16 | 2004-11-04 | Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University | Stable rgd peptidomimetic composition |
US7176185B2 (en) * | 2003-11-25 | 2007-02-13 | Tsrl, Inc. | Short peptide carrier system for cellular delivery of agent |
MXPA06011937A (en) | 2004-04-16 | 2007-01-26 | Sanol Arznei Schwarz Gmbh | Use of peptidic compounds for the prophylaxis and treatment of chronic headache. |
EP1604656A1 (en) * | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS) |
BRPI0514721A (en) * | 2004-08-27 | 2008-06-24 | Sanol Arznei Schwarz Gmbh | use of peptide compounds to treat bone cancer pain, chemotherapy-induced pain and nucleoside pain |
US20090010873A1 (en) * | 2004-11-29 | 2009-01-08 | Yeda Research And Development Co. Ltd. | Methods of Cell Therapy, Neurogenesis and Oligodendrogenesis |
US20060293218A1 (en) * | 2005-06-22 | 2006-12-28 | Meythaler Jay M | Salicylate therapeutic compound and process for controlled delivery thereof |
US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
EP1754476A1 (en) * | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
US20070048372A1 (en) * | 2005-08-18 | 2007-03-01 | Srz Properties, Inc. | Method for treating non-inflammatory osteoarthritic pain |
KR20150003925A (en) * | 2006-06-15 | 2015-01-09 | 유씨비 파르마 게엠베하 | Pharmaceutical composition with synergistic anticonvulsant effect |
WO2009111625A2 (en) * | 2008-03-05 | 2009-09-11 | Board Of Regents, The University Of Texas System | Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis |
ES2394035T3 (en) * | 2008-04-07 | 2013-01-15 | Auburn University | Methods for specific immunocontraception for certain animal species |
WO2010088527A2 (en) * | 2009-01-30 | 2010-08-05 | Mayo Foundation For Medical Education And Research | Peptides and nanoparticles for therapeutic and diagnostic applications |
DE102009002044A1 (en) * | 2009-03-31 | 2010-10-07 | Evonik Degussa Gmbh | Dipeptides as feed additives |
KR101080271B1 (en) * | 2009-03-31 | 2011-11-08 | 주식회사 웰스킨 | Ultraviolet-induced reaction controlling cosmetic composition containing dipeptide |
KR100953900B1 (en) * | 2009-08-28 | 2010-04-22 | 전북대학교산학협력단 | Cosmetic composition for improvement of dermatitis |
WO2011126163A1 (en) * | 2010-04-08 | 2011-10-13 | 주식회사 웰스킨 | Skin-whitening composition containing dipeptide |
US10005818B2 (en) * | 2010-07-21 | 2018-06-26 | Realta Holdings, Llc | Derivative peptide compounds and methods of use |
CA2804998C (en) | 2010-07-21 | 2018-11-13 | Eastern Virginia Medical School | Peptide compounds to regulate the complement system |
EP2612664A4 (en) * | 2010-09-02 | 2014-03-19 | Menicon Co Ltd | Stabilized polyphenol solution and method for stabilizing polyphenol solution |
WO2013131032A1 (en) * | 2012-03-02 | 2013-09-06 | Icahn School Of Medicine At Mount Sinai | Variants of prothymosin alpha and methods of using same |
KR102588702B1 (en) | 2013-03-15 | 2023-10-16 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Inhibition of Pulmonary Fibrosis with Nutlin-3a and Peptides |
EP2994156A4 (en) * | 2013-05-10 | 2017-01-11 | Southern Research Institute | Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity |
WO2016210370A2 (en) | 2015-06-26 | 2016-12-29 | Eastern Virginia Medical School | Synthetic peptide compounds and methods of use |
US10947279B2 (en) | 2015-06-26 | 2021-03-16 | Realta Holdings, Llc | Synthetic peptide compounds and methods of use |
US10464977B2 (en) * | 2016-04-11 | 2019-11-05 | University Of Maryland, Baltimore | Histatin-5 based synthetic peptides and uses thereof |
EP3576727A4 (en) * | 2017-02-01 | 2020-09-09 | The Johns Hopkins University | Prodrugs of glutamine analogs |
US11046729B2 (en) | 2017-10-26 | 2021-06-29 | Southern Research Institute | Dipeptide analogs as TGF-beta inhibitors |
CN108129561B (en) * | 2017-12-06 | 2021-05-25 | 渤海大学 | ACE inhibitory peptide |
KR20220104268A (en) | 2018-01-09 | 2022-07-26 | 레알타 홀딩스, 엘엘씨 | Pic1 inhibition of myeloperoxidase oxidative activity in an animal model |
WO2019208701A1 (en) * | 2018-04-26 | 2019-10-31 | ゼリア新薬工業株式会社 | Pharmaceutical composition containing dipeptide |
JP7496826B2 (en) | 2018-09-10 | 2024-06-07 | ラング セラピューティクス,エルエルシー | Modified peptide fragments of the CAV-1 protein and their use in the treatment of fibrosis - Patents.com |
GB202211935D0 (en) | 2022-08-16 | 2022-09-28 | Oxford Biomedica Ltd | envelope proteins |
CN117186173B (en) * | 2023-09-14 | 2024-04-05 | 海南大学 | Inhibition of Abeta 42 Tripeptide compounds that aggregate and reduce their cytotoxic effects |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986004334A1 (en) * | 1985-01-18 | 1986-07-31 | MERCK Patent Gesellschaft mit beschränkter Haftung | Immunoregulatory peptides |
WO1994024154A2 (en) * | 1993-04-09 | 1994-10-27 | Borella, Fabio | Immuno modulated peptide derivatives of leukokinin fragments |
WO1995003067A1 (en) * | 1993-07-21 | 1995-02-02 | Khavinson Vladimir Khatskelevi | Pharmaceutical with immunomodulating activity |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4244946A (en) * | 1979-06-11 | 1981-01-13 | The Salk Institute For Biological Studies | Water-soluble peptides affecting gonadal function |
US4305872A (en) * | 1979-10-19 | 1981-12-15 | Kenneth Wingrove | Polypeptide derivatives |
US4316891A (en) * | 1980-06-14 | 1982-02-23 | The Salk Institute For Biological Studies | Extended N-terminal somatostatin |
FR2529461B1 (en) * | 1982-07-02 | 1988-06-03 | Pasteur Institut | TRIPEPTIDE FROM AN IMMUNOGLOBULIN FRAGMENT, PREPARATION METHOD THEREOF AND APPLICATIONS THEREOF |
US5510329A (en) * | 1988-04-26 | 1996-04-23 | Ramot University For Applied Research And Industrial Development Ltd. | Preparations for the treatment of eyes |
US5506231A (en) * | 1989-03-31 | 1996-04-09 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
US5455279A (en) * | 1991-04-19 | 1995-10-03 | The Children's Medical Center Corporation | Regimen method of mediating neuronal damage using nitroglycerine |
-
1997
- 1997-05-28 US US08/864,301 patent/US6126939A/en not_active Expired - Fee Related
- 1997-09-03 CA CA002264285A patent/CA2264285A1/en not_active Abandoned
- 1997-09-03 AU AU40301/97A patent/AU4030197A/en not_active Abandoned
- 1997-09-03 JP JP10512435A patent/JP2001500492A/en active Pending
- 1997-09-03 EP EP97937794A patent/EP0927191A2/en not_active Withdrawn
- 1997-09-03 WO PCT/IL1997/000295 patent/WO1998009985A2/en not_active Application Discontinuation
- 1997-09-03 IL IL12852997A patent/IL128529A0/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986004334A1 (en) * | 1985-01-18 | 1986-07-31 | MERCK Patent Gesellschaft mit beschränkter Haftung | Immunoregulatory peptides |
WO1994024154A2 (en) * | 1993-04-09 | 1994-10-27 | Borella, Fabio | Immuno modulated peptide derivatives of leukokinin fragments |
WO1995003067A1 (en) * | 1993-07-21 | 1995-02-02 | Khavinson Vladimir Khatskelevi | Pharmaceutical with immunomodulating activity |
Non-Patent Citations (2)
Title |
---|
CHEMICAL ABSTRACTS, vol. 119, no. 9, 30 August 1993 Columbus, Ohio, US; abstract no. 93494, CHEIDO, M. A. ET AL: "Peptide modulation of immune responses" XP002052663 & EKSP. KLIN. FARMAKOL. (1993), 56(1), 51 CODEN: EKFAE9, 1993, * |
SIGMA Chemie Catalogus Biochemicalien Organische Verbindingen 1995 XP002052662 * |
Cited By (145)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
US9534032B2 (en) | 1998-10-23 | 2017-01-03 | Amgen Inc. | Thrombopoietic compounds |
US7189827B2 (en) | 1998-10-23 | 2007-03-13 | Amgen Inc. | Modified peptides as therapeutic agents |
US9145450B2 (en) | 1998-10-23 | 2015-09-29 | Amgen Inc. | Thrombopoietic compounds |
US7169905B2 (en) | 1998-10-23 | 2007-01-30 | Amgen Inc. | Modified peptides as therapeutic agents |
US7166707B2 (en) | 1998-10-23 | 2007-01-23 | Amgen Inc. | Modified peptides as therapeutic agents |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
WO2000077166A3 (en) * | 1999-06-10 | 2001-05-17 | Digital Gene Tech Inc | Gene expression modulated in gastrointestinal inflammation |
WO2000077166A2 (en) * | 1999-06-10 | 2000-12-21 | Digital Gene Technologies, Inc. | Gene expression modulated in gastrointestinal inflammation |
WO2001010457A3 (en) * | 1999-08-09 | 2001-08-30 | Tripep Ab | Pharmaceutical compositions containing tripeptides |
WO2001010456A3 (en) * | 1999-08-09 | 2001-09-20 | Tripep Ab | Peptides that block viral infectivity and methods of use thereof |
WO2001010457A2 (en) * | 1999-08-09 | 2001-02-15 | Tripep Ab | Pharmaceutical compositions containing tripeptides |
US6258932B1 (en) | 1999-08-09 | 2001-07-10 | Tripep Ab | Peptides that block viral infectivity and methods of use thereof |
WO2001010456A2 (en) * | 1999-08-09 | 2001-02-15 | Tripep Ab | Peptides that block viral infectivity and methods of use thereof |
US8133868B2 (en) | 1999-08-13 | 2012-03-13 | University Of Florida Research Foundation, Inc. | Dipeptides for prevention of muscle breakdown and microbial infection |
US7855181B2 (en) | 1999-08-13 | 2010-12-21 | University Of Florida Research Foundation, Inc. | Dipeptides for prevention of muscle breakdown and microbial infection |
EP2194137A2 (en) | 2000-04-19 | 2010-06-09 | Oxford BioMedica (UK) Limited | Cells comprising codon optimized retroviral particles |
JP4860096B2 (en) * | 2000-08-10 | 2012-01-25 | エス・アイ・エス・シユロブ・インステイテユート・フオー・サイエンス・リミテツド | Pharmaceutical composition comprising an analgesic peptide |
JP2004513079A (en) * | 2000-08-10 | 2004-04-30 | エス・アイ・エス・シユロブ・インステイテユート・フオー・サイエンス・リミテツド | Pharmaceutical composition comprising an analgesic peptide |
EP2202240A1 (en) | 2000-08-18 | 2010-06-30 | Sterix Limited | Compound |
EP1472276A2 (en) * | 2001-02-28 | 2004-11-03 | Keith M. Skubitz | Small peptides capable of modulating the function of cd66 (ceacam) family members |
EP1472276A4 (en) * | 2001-02-28 | 2007-05-09 | Keith M Skubitz | Small peptides capable of modulating the function of cd66 (ceacam) family members |
GB2391548B (en) * | 2001-04-18 | 2005-11-30 | Univ Open | Polypeptides and derivatives thereof related to amyloid precursor protein (APP) |
EP2228388A1 (en) * | 2001-04-18 | 2010-09-15 | The Open University | Protected Arg-Glu-Arg polypeptides and uses thereof |
GB2391548A (en) * | 2001-04-18 | 2004-02-11 | Univ Open | Polypeptides derived from amyloid precursor peptide (APP) and their uses |
US7491702B2 (en) | 2001-04-18 | 2009-02-17 | The Open University | Polypeptides related to amyloid precursor protein, pharmaceutical compositions thereof, and methods of treatment using the same |
WO2002083729A3 (en) * | 2001-04-18 | 2003-07-31 | Univ Open | Polypeptides derived from amyloid precursor peptide (app) and their uses |
US7622446B2 (en) | 2001-04-18 | 2009-11-24 | The Open University | Polypeptides, derivatives and uses thereof |
US6969598B2 (en) | 2001-04-30 | 2005-11-29 | Oxford Biomedica (Uk) Limited | Methods for producing high titre vectors and compositions used in such methods |
US6593455B2 (en) | 2001-08-24 | 2003-07-15 | Tripep Ab | Tripeptide amides that block viral infectivity and methods of use thereof |
US7605132B2 (en) | 2001-08-29 | 2009-10-20 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Protective factors against inflammation, burns and noxious stimuli |
US7012129B2 (en) | 2001-09-19 | 2006-03-14 | Tripep Ab | Antiviral composition comprising glycine amide |
EP2348119A2 (en) | 2002-02-01 | 2011-07-27 | Oxford BioMedica (UK) Limited | Multicistronic lentiviral vector |
WO2003064665A2 (en) | 2002-02-01 | 2003-08-07 | Oxford Biomedica (Uk) Limited | Viral vector |
WO2004002417A2 (en) | 2002-06-28 | 2004-01-08 | Centocor, Inc. | Mammalian ch1 deleted mimetibodies, compositions, methods and uses |
US7148199B2 (en) | 2003-09-26 | 2006-12-12 | University Of Florida Research Foundation, Inc. | Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
US7754692B2 (en) | 2003-09-26 | 2010-07-13 | University Of Florida Research Foundation, Inc. | Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
WO2005030243A1 (en) * | 2003-09-26 | 2005-04-07 | Bristol Myers Squibb Company | Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
WO2005030242A1 (en) * | 2003-09-26 | 2005-04-07 | University Of Florida Research Foundation, Inc | Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
WO2005090387A3 (en) * | 2004-03-23 | 2006-02-02 | Univ Jerusalem Yissum Res Dev | Histone h2a peptide derivatives and analogs and methods of use thereof |
US7528227B2 (en) | 2004-03-23 | 2009-05-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Histone H2A peptide derivatives and uses thereof |
WO2005090387A2 (en) * | 2004-03-23 | 2005-09-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Histone h2a peptide derivatives and analogs and methods of use thereof |
WO2005115996A1 (en) | 2004-05-24 | 2005-12-08 | Sterix Limited | Sulfamic acid ester compounds useful in the inhibition of seroid sulphatase activity and aromatase activity |
US8470860B2 (en) | 2004-06-04 | 2013-06-25 | Sterix Limited | Phenyl-sulfamates as aromatase inhibitors |
US8143380B2 (en) | 2004-07-08 | 2012-03-27 | Amgen Inc. | Therapeutic peptides |
US7989590B2 (en) | 2005-03-22 | 2011-08-02 | Rohto Pharmaceutical Co., Ltd | Peptides that increase collagen or hyaluronic acid production |
WO2006101187A1 (en) * | 2005-03-22 | 2006-09-28 | Rohto Pharmaceutical Co., Ltd. | Peptides that increase collagen or hyaluronic acid production |
US8871717B2 (en) | 2005-04-27 | 2014-10-28 | The Procter & Gamble Company | Personal care compositions |
WO2006116731A3 (en) * | 2005-04-27 | 2006-12-14 | Procter & Gamble | Personal care compositions comprising a dipeptide |
AU2014271339B2 (en) * | 2005-04-27 | 2016-11-03 | The Procter & Gamble Company | Personal care compositions |
US10130577B2 (en) | 2005-04-27 | 2018-11-20 | The Procter & Gamble Company | Personal care compositions |
WO2006116731A2 (en) * | 2005-04-27 | 2006-11-02 | The Procter & Gamble Company | Personal care compositions comprising a dipeptide |
US11753643B2 (en) | 2005-05-27 | 2023-09-12 | Ospedale San Raffaele S.R.L. | Gene vector |
EP3002330A1 (en) | 2005-05-27 | 2016-04-06 | Ospedale San Raffaele S.r.l. | Gene vector |
US9556438B2 (en) | 2005-05-27 | 2017-01-31 | Fondazione Centro San Raffaele Del Monte Tabor | Gene vector |
US10000757B2 (en) | 2005-05-27 | 2018-06-19 | Ospedale San Raffaele S.R.L. | Gene vector |
US8119627B2 (en) | 2005-07-04 | 2012-02-21 | Sterix Limited | Heterocyclic compounds as inhibitors of 17beta-HSD3 |
US10188740B2 (en) | 2005-08-12 | 2019-01-29 | Amgen Inc. | Modified Fc molecules |
US11266744B2 (en) | 2005-08-12 | 2022-03-08 | Amgen Inc. | Modified Fc molecules |
FR2894142A1 (en) * | 2005-12-05 | 2007-06-08 | Oreal | Use of a combination of niacinamide and tyrosine-arginine dipeptide or its derivatives e.g. to prevent and/or decrease cutaneous rednesses and/or swellings |
EP1795181A1 (en) | 2005-12-05 | 2007-06-13 | L'Oréal | Cosmetic and pharmaceutical uses of the dipeptide tyrosine-arginine in combination with niacinamide as substance P antagonist |
US8858968B2 (en) | 2005-12-05 | 2014-10-14 | L'oreal | Use of tyrosine-arginine dipeptide and niacinamide as substance P antagonist |
US8512694B2 (en) | 2005-12-21 | 2013-08-20 | Bioeos Limited | Method of producing rough strains of bacteria and uses thereof |
EP2298860A2 (en) | 2005-12-21 | 2011-03-23 | BioEos Limited | Method of producing rough strains of bacteria and uses thereof |
US8071354B2 (en) | 2005-12-21 | 2011-12-06 | Bioeos Limited | Method of producing rough strains of bacteria and uses thereof |
WO2007072056A2 (en) | 2005-12-22 | 2007-06-28 | Oxford Biomedica (Uk) Limited | Vectors |
US7968561B2 (en) | 2006-03-01 | 2011-06-28 | Sterix Limited | Steroidal compounds as steroid sulphatase inhibitors |
EP2594284A1 (en) | 2006-04-21 | 2013-05-22 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
EP2594285A1 (en) | 2006-04-21 | 2013-05-22 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
EP2594286A1 (en) | 2006-04-21 | 2013-05-22 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
EP2594288A1 (en) | 2006-04-21 | 2013-05-22 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
US10166189B2 (en) | 2006-04-21 | 2019-01-01 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
EP2594287A1 (en) | 2006-04-21 | 2013-05-22 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
US8524674B2 (en) | 2006-05-30 | 2013-09-03 | Obschestvo S Ogranichennoi Otvetstvennostyu “SIA Peptides” | Method of improving the conditioned reflex habit, the muscle tonus, or the motion coordination of a patient after suffering trauma to the brain cortex |
US20090105157A1 (en) * | 2006-05-30 | 2009-04-23 | Obschestvo Ogranichennoi Otvetstennostyu Sia Peptides | Peptide substance stimulating regeneration of central nervous system neurons, pharmaceutical composition on its base, and the method of its application |
US8642295B2 (en) | 2007-01-11 | 2014-02-04 | Erasmus University Medical Center | Circular chromosome conformation capture (4C) |
WO2008096276A3 (en) * | 2007-02-02 | 2009-03-19 | Greenpharma Sas | Peptide inhibitors of metallo- ectopeptidases, compositions comprising said compounds and their pharmaceutical and cosmetic uses |
WO2008096155A1 (en) | 2007-02-08 | 2008-08-14 | Sterix Limited | Composition comprising a glycolytic inhibitor and a ring system comprising a sulphamate group for the treatment of cancer |
US8394825B2 (en) | 2007-03-28 | 2013-03-12 | Sterix Limited | Compound |
US8558028B2 (en) | 2007-11-20 | 2013-10-15 | University Of Bath Of Claverton Down | Compound capable of inhibiting 17-beta hydroxysteriod dehydrogenase |
WO2009123486A1 (en) * | 2008-04-01 | 2009-10-08 | Bioalvo - Serviços, Investigação E Desenvolvimento Em Biotecnologia S.A. | Use of compounds in the treatment of tau-induced cytotoxicities |
EP3192874A1 (en) | 2008-06-18 | 2017-07-19 | Oxford BioMedica (UK) Limited | Virus purification |
WO2010055413A1 (en) | 2008-11-12 | 2010-05-20 | Fondazione Centro San Raffaele Del Monte Tabor | Gene vector for inducing transgene-specific immune tolerance |
EP3733214A1 (en) | 2009-04-30 | 2020-11-04 | Ospedale San Raffaele S.r.l. | Gene vector |
US8846737B2 (en) | 2009-08-24 | 2014-09-30 | Sterix Limited | Compound |
WO2011023989A1 (en) | 2009-08-24 | 2011-03-03 | Sterix Limited | Aromatase inhibitor |
WO2012156839A2 (en) | 2011-05-19 | 2012-11-22 | Ospedale San Raffaele S.R.L. | New generation of splice-less lentiviral vectors for safer gene therapy applications |
CN102796165B (en) * | 2011-05-24 | 2014-02-26 | 首都医科大学 | Arg-Tyr modified aliphatic amine/ alcohol derivatives and preparation method and application thereof |
CN102796165A (en) * | 2011-05-24 | 2012-11-28 | 首都医科大学 | Arg-Tyr modified aliphatic amine/ alcohol derivatives and preparation method and application thereof |
US9493528B2 (en) * | 2013-01-10 | 2016-11-15 | Supadelixir Inc. | Microphthalmia-associated transcription factor-derived peptide and composition containing same |
US20160002308A1 (en) * | 2013-01-10 | 2016-01-07 | Supadelixir Inc. | Microphthalmia-associated transcription factor-derived peptide and composition containing same |
WO2014140934A2 (en) | 2013-03-11 | 2014-09-18 | Life Science Nutrition As | Natural lipids containing non-oxidizable fatty acids |
EP3613859A1 (en) | 2013-10-24 | 2020-02-26 | Ospedale San Raffaele S.r.l. | Method |
US10617721B2 (en) | 2013-10-24 | 2020-04-14 | Ospedale San Raffaele S.R.L. | Methods for genetic modification of stem cells |
EP3587582A1 (en) | 2013-10-24 | 2020-01-01 | Adaptimmune Limited | Vectors for transgene expression |
EP3650548A1 (en) | 2013-12-20 | 2020-05-13 | Oxford BioMedica (UK) Limited | Viral vector production system |
US10391201B2 (en) | 2014-04-25 | 2019-08-27 | Ospedale San Raffaele Srl | Gene therapy |
WO2016009326A1 (en) | 2014-07-14 | 2016-01-21 | Ospedale San Raffaele S.R.L | Vector production |
US11957747B2 (en) | 2014-07-14 | 2024-04-16 | Ospedale San Raffaele S.R.L. | Vector production |
US10912824B2 (en) | 2014-07-14 | 2021-02-09 | Ospedale San Raffaele S.R.L. | Vector production |
EP3995584A1 (en) | 2014-10-24 | 2022-05-11 | Ospedale San Raffaele S.r.l. | Gene silencing |
WO2016063264A1 (en) | 2014-10-24 | 2016-04-28 | Ospedale San Raffaele S.R.L. | Permanent epigenetic gene silencing |
US12059478B2 (en) | 2016-05-20 | 2024-08-13 | Ospedale San Raffaele S.R.L. | Gene therapy |
US11939398B2 (en) | 2016-08-16 | 2024-03-26 | Neuro-Bio Ltd | Modified peptides for use in treating neurodegenerative disorders |
EP3549595A4 (en) * | 2016-12-05 | 2020-07-22 | Otsuka Pharmaceutical Co., Ltd. | Amyotrophy inhibiting composition |
US11331366B2 (en) | 2016-12-05 | 2022-05-17 | Otsuka Pharmaceutical Co., Ltd. | Composition for suppressing muscular atrophy |
EP3973996A1 (en) | 2017-04-21 | 2022-03-30 | Ospedale San Raffaele S.r.l. | Gene therapy |
WO2018193118A1 (en) | 2017-04-21 | 2018-10-25 | Ospedale San Raffaele S.R.L | Gene therapy |
EP3682891A4 (en) * | 2017-09-15 | 2021-07-21 | Kine Sciences Co., Ltd. | Use of peptides as therapeutic agent for autoimmune diseases and bone diseases |
CN111093687A (en) * | 2017-09-15 | 2020-05-01 | 凯恩塞恩斯株式会社 | Use of peptides as therapeutic agents for autoimmune diseases and bone diseases |
US11730788B2 (en) | 2017-09-15 | 2023-08-22 | Kine Sciences Co., Ltd. | Use of peptides as therapeutic agent for autoimmune diseases and bone diseases |
CN111093687B (en) * | 2017-09-15 | 2024-07-09 | 凯恩塞恩斯株式会社 | Use of peptides as therapeutic agents for autoimmune diseases and bone diseases |
AU2018333776B2 (en) * | 2017-09-15 | 2022-07-07 | Kine Sciences Co., Ltd. | Use of peptides as therapeutic agent for autoimmune diseases and bone diseases |
WO2019219836A1 (en) | 2018-05-16 | 2019-11-21 | Ospedale San Raffaele S.R.L. | Virus vector production |
WO2019219838A1 (en) | 2018-05-16 | 2019-11-21 | Ospedale San Raffaele S.R.L. | Compositions and methods for haematopoietic stem cell transplantation |
WO2020002380A1 (en) | 2018-06-25 | 2020-01-02 | Ospedale San Raffaele S.R.L | Gene therapy |
WO2020074729A1 (en) | 2018-10-11 | 2020-04-16 | Ospedale San Raffaele S.R.L | Selection by means of artificial transactivators |
WO2020148445A1 (en) | 2019-01-18 | 2020-07-23 | Société des Produits Nestlé S.A. | Agents and methods for increasing stem cell function |
WO2021094752A1 (en) | 2019-11-12 | 2021-05-20 | Oxford Biomedica (Uk) Limited | Production system |
WO2021160993A1 (en) | 2020-02-13 | 2021-08-19 | Oxford Biomedica (Uk) Limited | Production of lentiviral vectors |
WO2021181108A1 (en) | 2020-03-13 | 2021-09-16 | Oxford Biomedica (Uk) Limited | Lentiviral vectors |
WO2021229237A1 (en) | 2020-05-14 | 2021-11-18 | Ucl Business Ltd | Cyclosporine analogues |
WO2021229242A1 (en) | 2020-05-15 | 2021-11-18 | Oxford Biomedica (Uk) Limited | Viral vector production |
WO2022064063A1 (en) | 2020-09-28 | 2022-03-31 | Société des Produits Nestlé S.A. | Compositions and methods for increasing stem cell function |
WO2022064061A1 (en) | 2020-09-28 | 2022-03-31 | Société des Produits Nestlé S.A. | Compositions and methods for increasing stem cell function |
WO2022101617A1 (en) | 2020-11-10 | 2022-05-19 | Oxford Biomedica (Uk) Limited | Preparation of a solution of polymer/nucleic acid complexes |
CN112724238A (en) * | 2021-01-21 | 2021-04-30 | 浙江辉肽生命健康科技有限公司 | Bioactive peptide with amino acid structure FREGTTPKPK, and preparation method and application thereof |
WO2022162247A1 (en) | 2021-02-01 | 2022-08-04 | Epsilen Bio S.R.L. | Gene silencing |
WO2022229227A1 (en) | 2021-04-28 | 2022-11-03 | Ospedale San Raffaele S.R.L. | Compositions for improving the transduction of cells by viral vectors |
WO2022233767A1 (en) | 2021-05-05 | 2022-11-10 | Société des Produits Nestlé S.A. | Urolithin for increasing stem cell function |
GB202114530D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Retroviral vectors |
WO2023062367A1 (en) | 2021-10-12 | 2023-04-20 | Oxford Biomedica (Uk) Limited | Lentiviral vectors |
WO2023062359A2 (en) | 2021-10-12 | 2023-04-20 | Oxford Biomedica (Uk) Limited | Novel viral regulatory elements |
WO2023062365A2 (en) | 2021-10-12 | 2023-04-20 | Oxford Biomedica (Uk) Limited | Lentiviral vectors |
WO2023062366A1 (en) | 2021-10-12 | 2023-04-20 | Oxford Biomedica (Uk) Limited | Retroviral vectors |
GB202114529D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral vectors |
WO2023062363A1 (en) | 2021-10-12 | 2023-04-20 | Oxford Biomedica (Uk) Limited | Lentiviral vectors |
GB202114532D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral Vectors |
WO2023066735A1 (en) | 2021-10-19 | 2023-04-27 | Ospedale San Raffaele S.R.L. | Gene therapy |
WO2023105235A1 (en) | 2021-12-09 | 2023-06-15 | Oxford Biomedica (Uk) Limited | Purification method of viral vectors |
WO2023209223A1 (en) | 2022-04-28 | 2023-11-02 | Ospedale San Raffaele S.R.L. | Methods for haematopoietic stem cell transplantation |
WO2023209225A1 (en) | 2022-04-29 | 2023-11-02 | Ospedale San Raffaele S.R.L. | Gene therapy |
WO2023247937A1 (en) | 2022-06-21 | 2023-12-28 | Ucl Business Ltd | Cyclosporine analogues |
WO2024079644A1 (en) | 2022-10-11 | 2024-04-18 | Fondazione Telethon Ets | 3d cell culture methods |
Also Published As
Publication number | Publication date |
---|---|
CA2264285A1 (en) | 1998-03-12 |
WO1998009985A3 (en) | 1998-05-07 |
IL128529A0 (en) | 2000-01-31 |
US6126939A (en) | 2000-10-03 |
EP0927191A2 (en) | 1999-07-07 |
JP2001500492A (en) | 2001-01-16 |
AU4030197A (en) | 1998-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6126939A (en) | Anti-inflammatory dipeptide and pharmaceutical composition thereof | |
RU2060998C1 (en) | Method of synthesis of peptides, peptides, immunomodulating composition and a method of regulation of insufficient or excessive function of t-cells in patient | |
EP1560590B1 (en) | Synthetic complementary peptides and ophthalmologic uses thereof | |
US6096713A (en) | Pharmaceutical angiostatic dipeptide compositions and methods of use thereof | |
JP2002501537A (en) | Sulfonamides as cell adhesion inhibitors | |
US5190922A (en) | Terminally modified tri-, tetra- and pentapeptide anaphylatoxin receptor ligands | |
JPH01190699A (en) | Platelet coagulation inhibitor peptide derivative | |
MXPA97003643A (en) | Methods for the treatment of multiple sclerosis using basic protein peptide analogues human human protein | |
WO1994007815A2 (en) | Small peptide anaphylatoxin receptor ligands | |
EP0564588B1 (en) | Hexapeptide anaphylatoxin-receptor ligands | |
JP2000512277A (en) | Peptide derivative | |
US5387671A (en) | Hexa- and heptapeptide anaphylatoxin-receptor ligands | |
US5223485A (en) | Anaphylatoxin-receptor ligands | |
US20080171060A1 (en) | Modulation of immune response and methods based thereon | |
CA1280379C (en) | Peptides and compositions | |
WO1995003067A1 (en) | Pharmaceutical with immunomodulating activity | |
EP0297456A2 (en) | Immunosuppressant peptides | |
RU2163242C2 (en) | Cyclohexapeptides, mixtures thereof, and method of preparing thereof | |
WO1995025537A1 (en) | Drug for relieving side effects caused by immunosuppressants | |
AU721261B2 (en) | Peptide inhibitors of hematopoietic cell proliferation | |
US5663148A (en) | Anaphylatoxin receptor ligands containing lipophilic residues | |
WO1994007518A1 (en) | Anaphylatoxin receptor ligands containing lipophilic residues | |
JPS62501502A (en) | immunomodulatory peptides | |
RU2036930C1 (en) | Peptides and composition on their base capable to regulate immune function in mammalian | |
WO1998009984A1 (en) | Central nervous system-derived immune privilege factor and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2264285 Country of ref document: CA Ref country code: CA Ref document number: 2264285 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 512435 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/002057 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09261368 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997937794 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997937794 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997937794 Country of ref document: EP |